This is consistent with studies in the Dutch Arthritis and Biologics in Children register [6] and the German Biologics JIA Registry [37], as well as in line with recent EULAR recommendations for RA, where earlier treatment with anti-TNF inhibitors in patients who have failed to reach low disease activity with nbDMARDs is recommended [38]. Here, TNF is linked to juvenile idiopathic arthritis.